



Digital Health Ecosystem Key Trends

Middle East


H1 2021 Report

Investment Trends • Pipeline Maturity • Category Focus
Therapeutic Focus • Noteworthy Deals • Partnerships And Investors





In our fast-changing environment, we are driven to empower the world's leading companies & investors to unleash the value of the digital health ecosystem to deliver better outcomes for businesses, customers & society.



Tailored Innovation Solutions

Our solutions have been road-tested across numerous successful projects. Powered by our deep industry insights, we offer clients a full suite of tailored HealthTech innovation programmes.

Digital Health 360 delivers access to the world's most up-to-date and comprehensive digital health intelligence.

Innovation Playbook gives corporates a strategic view of HealthTech, including market-level reviews, competitive benchmarking and partnership development to strengthen the innovation funnel.

Innovation Xplorer our annual membership, gives corporates the business intelligence & research, scouting, benchmarking, and events to build HealthTech capabilities across the entire organisation.

Accelerator Programme fast tracks the corporate Digital Health journey from venture selection and prototyping into successful execution scaling.

[Talk to us](#)



Foreword

We are very pleased to share with you our H1 2021 Middle East Digital Health Ecosystem report: the deep dive, go-to-reference reportage on key digital health ecosystems across the region.

As the world is progressing towards an endemic situation, the investments in digital health innovations continued to surge to improve tools and services that will increase access to diagnose, cure, care, and lower the rising healthcare costs across the globe. So far this year a total of US\$21.8B in venture capital funding, excluding M&A, IPO and SPAC activities, has continued the strong upward trajectory in investments that kicked off in the second half of year and closed at 2.2x from H1 2020.

The Middle East Digital Health ecosystem continues to grow year on year, with a recorded total of \$728M in venture capital funding invested in the past 6 months, up 2.24x YoY as compared to and up 2.60x compared to H1 2019.

Funding of digital health innovations targeting a specific therapeutic focus area has already surpassed the total invested in 2020 to reach \$671M an increase of 69%.

Despite the funding hike in the Middle East, digital health ventures continue to seek regulatory approval across other regions, including the United States and Europe. Till date, we have not recorded any digital health regulatory approval in the Middle East.

In this report, we focus our analysis on the venture funding key trends, noteworthy deals, exits, partnerships and investors as well as deep dive into four key focus areas for the region in H1 2021.

With unmatched, unparalleled and indispensable coverage of the global digital health ecosystems, this report is powered by HealthTech Alpha, a Galen Growth proprietary solution, and the world's leading on-demand digital health intelligence platform.

“

Probably the industry's most comprehensive and accurate ecosystem reports

”

Contents

Ecosystem Insights	6
Investment Trends	15
Cluster Focus	18
Therapeutic Focus	24
Deep Dive	26
Noteworthy	39
Key Information	44
About Galen Growth	48

Middle East

Ecosystem Insights



IN THE FIRST HALF OF 2021

\$727.7M


OF TOTAL FUNDING WERE DEPLOYED ACROSS

30 DEALS

IN THE MIDDLE EAST

Global Funding Across Regions

In H1 2021, cumulative digital health venture funding across the Middle East, Europe key markets, APAC and North America closed at \$21.8B, up 2.2x compared to H1 2020. Middle East represented 3.3% of the funding invested across four regions.





MIDDLE EAST: ECOSYSTEM INSIGHTS

H1 2021 Funding Distribution

Country*	Total Funding
Israel	\$722.1M ↗
Lebanon	\$3.0M ↗
United Arab Emirates	\$2.1M ↘
Bahrain	\$0.5M ↗

↗ ↘ YoY Change *Only countries with live data are included in this list.




Note: percentages may not total 100 due to rounding

©2021 by Galen Growth - All rights reserved.


Ecosystem Overview

9% the global digital health ventures are headquartered in the Middle East. Since 2016, the number of ventures in APAC has grown by 52% to reach 610 ventures in H1 2021 (excluding ventures that have been acquired or issued an IPO), with the lion share incorporated in Israel. The funding trajectory in the Middle East is slower than in other parts of the world, with only approximately 20% of ventures incorporated in 2018, raising Series A and later funding rounds.


Global Proportion of Ventures



Cumulative No. of Ventures



Venture Distribution by Inc. Year and Stage




Global Context: Regulatory Overview

In the first half of 2021, 43 ventures received regulatory approvals globally, with 1 venture receiving approval in multiple regions. While not all digital health solutions require regulatory approval, the Medical Diagnostics cluster, which includes Medical Imaging, Diagnosis Tools, Genomics-related Diagnosis, and Liquid Biopsy, recorded the most approvals in the first half of the year.

Region	# of Ventures with Regulatory Approvals
Asia Pacific	14
Europe	17
N. America	13


Venture Clusters with Regulatory Approvals in H1 2021




Global Context: Partnerships Overview

227 partnerships were announced globally in H1 2021 for Digital Health ventures. More than 50% of the partnerships involved ventures with solutions in Health Management Solutions, Patient Solutions, Research or Telemedicine.

Partnership Distribution by Cluster




Partnership Distribution by Geography




Global Context: Large Funding Events

2021 started with an unprecedented flurry of M&A activity in January, capped with several SPACs. The SPAC activity has continued throughout H1 along with an elevated volume of M&As and IPOs. Even more notable is that mega deals (>\$100M) in the first 2 quarters of 2021 have risen 2.6x over the Q1 2020 levels and 5x over the Q2 2020 levels, building on the mega-deal trend that started in Q3 2019.

Historical Volume of Mega Deals




Volume of Investor Exits (IPO, M&A, SPAC)



Global Context: Public Digital Health Ventures

Despite the recent boom in Digital Health venture IPOs and SPACs in the first half of the year, the stock development of digital health demonstrates a massive difference between those which succeed and those which fail to deliver. The TOP10 venture stocks increased by more than 100% in the past 6 months, while the bottom 10% lost more than 50% of their market value.

[Senseonics](#), up more than 300% since January this year, represented the stock with largest gain, fueled primarily by retail investors. In total, 22 ventures went public in the first half of 2021, while a few more have announced their exit in the next few months, including [Babylon Health](#) that will list through a \$4.2 billion merger with Alkuri Global Acquisition Corp (SPAC) later this year.



Note: The analysis is based on 117 digital health stocks that went public after 2005

Middle East




Investment Trends



MIDDLE EAST: INVESTMENT TRENDS


Digital Health Funding History

- Digital Health venture capital deployed in Middle East closed at **\$727.7M in H1 2021**, up 2.2x YoY compared to total funding of \$324.8M in H1 2020
- **Q1 and Q2 2021 represented the largest quarters in history**, with Q1 2021 up 2.4x YoY as compared to Q1 2020 and Q2 2021 up 2.1x as compared to Q2 2020
- Total venture deal volume closed at **30 deals**
- H1 2021 saw the **highest average deal size in history**, at **\$24.3M**, up 2.5x YoY as compared to \$9.6M in H1 2020
- **2 Mega Deals** (≥\$100M) were closed in Middle East in H1 2021




MIDDLE EAST: INVESTMENT TRENDS

Quarter-on-Quarter Digital Health Funding




Middle East

Cluster Focus




MIDDLE EAST: CLUSTER FOCUS

Our Taxonomy



Most Funded Digital Health Clusters (By Value)

With over \$720M invested, the 5 most funded Digital Health Clusters represented approximately 94% of the total funding raised in H1 2021 in Middle East.



Most Funded Clusters in 2021 (H1)

Rank	Cluster	Value	Largest Deal in Middle East
1	Medical Diagnostics	\$375.0 M	K Health \$132.0M (Series E)
2	Patient Solutions	\$149.5 M	Hello Heart \$45.0M (Series C)
3	Remote Monitoring	\$100.0 M	TytoCare \$50.0M (Series D1)
4	Safety & Security	\$30.0 M	Cynerio \$30.0M (Series B)
5	InsurTech	\$26.1 M	TailorMed \$20.0M (Series B)

MIDDLE EAST: CLUSTER FOCUS

Venture Maturity in Key Clusters

Across the top key regions, venture maturity can be measured using the Alpha Score, which is Galen Growth's proprietary algorithm that considers the venture momentum, innovation, market and funding.

- At \$375M, **Medical Diagnostics** attracted the most funding in H1 2021 and is also the **most populated cluster at 142 ventures**. A significant proportion of ventures have a maturity score between 31-44. The average maturity score for this cluster is **46.9**.
- The **Patient Solutions** cluster attracted the **second most funding in H1 2021** at \$149.5M and is the third most populated cluster, with an average maturity score of **45.1**.
- At 122 ventures, **Remote Monitoring** forms the **second most populated cluster** and has an average maturity score of **45.5**.
- While there is a low volume of 11 InsurTech ventures, **InsurTech** has the **highest maturity out of the TOP5 funded clusters at 49.1**.


Distribution of Ventures by Venture Maturity




Top Ventures in Key Clusters

In the Middle East, the largest Digital Health cluster is Medical Diagnostics, with 142 ventures. With 368 ventures, the three most populated clusters, Medical Diagnostics, Remote Monitoring and Patient Solutions, represent more than 60% of all digital health ventures in the Middle East.

Market Map of Key Clusters



Deal Volume Heatmap by Digital Health Cluster



Middle East


Therapeutic Focus



MIDDLE EAST: THERAPEUTIC FOCUS

Highest Funded Therapeutic Focus Areas

\$671M of the total venture capital funding were deployed across therapeutic focus specific solutions. Oncology overtook Cardiovascular Diseases as the highest funded therapeutic focus area in H1 2021. Diabetes funding rose from \$3.3M in 2020 to \$113.0M, with 3 Series C deals in H1 2021. Most of the funding in the TOP5 therapeutic focus areas in H1 2021 were deployed in Growth & Late Stages.



Deep Dive

Therapeutic Focus Areas



Oncology



Cardiovascular Diseases

Digital Health Clusters




Medical Diagnostics



Patient Solutions

Deep Dive:


Oncology



Oncology


In the Middle East, 31 ventures offer Oncology-focused digital health solutions, with 29 of the ventures in Israel. Since 2017, the number of Oncology ventures has grown by 63%. The total funding of \$154M was entirely raised in Israel and across Series B and Series C stages.

Proportion of Oncology Ventures in the Middle East




- Oncology
- Other Therapeutic Focus Areas

Venture Distribution by Country, H1 2021



Cumulative No. of Ventures, 2016 - 2020



* Ventures with multiple solutions may be classified in more than 1 category

Venture Spotlight



C2i Genomics


COUNTRY	PRIMARY CATEGORY
Israel	Genomics Related Diagnosis
LATEST FUNDING	VALUATION*
\$100.0M (Series B)	\$480.0M
INC. DATE	MATURITY SCORE
9/2019	71.1

DESCRIPTION


C2i Genomics offers post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor's DNA. Based on bioinformatics and artificial intelligence, C2i Genomics compares thousands of data points obtained from patients' periodic liquid biopsy blood tests to their own baseline of sequenced tumor tissue and whole-genome analysis.

Oncology

Middle East Value of Venture Capital Investment in Oncology



Total Funding Distribution (2017 - H1 2021) by Country in the Middle East




Venture Spotlight

IBEX


Ibex Medical Analytics

COUNTRY	PRIMARY CATEGORY
Israel	Medical Imaging
LATEST FUNDING	VALUATION*
\$38.0M (Series B)	\$182.4M
INC. DATE	MATURITY SCORE
12/2017	71.7

Middle East Oncology Investment Volume Share by Venture Stage



Total Funding Distribution (2017 - H1 2021) by District in Israel



Deep Dive:


Cardiovascular Diseases



Cardiovascular Diseases


35 ventures in the Middle East are focused on Cardiovascular Disease-focused digital health solutions, all of which are headquartered in Israel. The total of \$70M invested in H1 2021 was deployed across two deals.

Proportion of Cardiovascular Diseases Ventures in the Middle East




- Cardiovascular Diseases
- Other Therapeutic Focus Areas

Venture Distribution by Country, H1 2021



Cumulative No. of Ventures, 2016 - 2020



Venture Spotlight



TytoCare


COUNTRY	PRIMARY CATEGORY
Israel	Remote Monitoring Devices
LATEST FUNDING	VALUATION*
\$50.0M (Series D1)	\$434.6M
INC. DATE	MATURITY SCORE
1/2011	73.4

DESCRIPTION


TytoCare aims to transform primary care by putting health in the hands of consumers. TytoCare offers a remote examination tool and telehealth platform that enables a complete examination of the heart, lungs, skin, throat, and ears, including temperature readings, anywhere and anytime.

Cardiovascular Diseases

Middle East Value of Venture Capital Investment in Cardiovascular Diseases



Total Funding Distribution (2017 - H1 2021) by Country in the Middle East




Venture Spotlight




Hello Heart

COUNTRY	PRIMARY CATEGORY
Israel	Disease Management
LATEST FUNDING	VALUATION*
\$45.0M	\$264.7M
INC. DATE	MATURITY SCORE
10/2017	70.6

Middle East Cardiovascular Diseases Investment Volume Share by Venture Stage



Total Funding Distribution (2017 - H1 2021) by District in Israel



DESCRIPTION

Hello Heart is a clinically based smartphone solution that allows patients to track, understand, and improve their chronic conditions. The easy-to-use app helps users build healthy tracking habits and improve their health in real time, empowering them to identify health risks early for potentially lifesaving results.

Deep Dive:


Medical Diagnostics



Medical Diagnostics


In the Middle East, 142 ventures are providing digital health solutions for Medical Diagnostics. As of H1 2021, Medical Diagnostics is the largest and most funded cluster in the Middle East, representing 22% of all ventures in the Middle East and with \$375M of funding deployed in H1 2021. 96% of the ventures are headquartered in Israel, and all \$375M raised in H1 2021 was by ventures headquartered in Israel.

Proportion of Medical Diagnostics Ventures in the Middle East




- Medical Diagnostics
- Other Digital Health Categories

Venture Distribution by Country, H1 2021



Cumulative No. of Ventures, 2016 - 2020



* Ventures with multiple solutions may be classified in more than 1 category

Venture Spotlight



K Health


COUNTRY	PRIMARY CATEGORY
Israel	Diagnosis Tools
LATEST FUNDING	VALUATION*
\$132.0M (Series E)	\$1.02B
INC. DATE	MATURITY SCORE
8/2015	78.7

DESCRIPTION


K Health developed K, an AI personal health assistant powered by millions of real medical charts, notes, and labs. K shows patients how doctors have diagnosed and treated other people with similar cases. K can address a wide variety of symptoms and primary-care outpatient conditions.

Medical Diagnostics

Middle East Value of Venture Capital Investment in Medical Diagnostics



Total Funding Distribution (2017 - H1 2021) by Country in the Middle East




Venture Spotlight

Augmedics


Augmedics

COUNTRY	PRIMARY CATEGORY
Israel	Medical Imaging
LATEST FUNDING	VALUATION*
\$36.0M (Series C)	\$211.8M
INC. DATE	MATURITY SCORE
8/2014	71.4

Middle East Medical Diagnostics Investment Volume Share by Venture Stage



Total Funding Distribution (2017 - H1 2021) by District in Israel



DESCRIPTION

Augmedics is developing xvision, an augmented reality system that allows surgeons to fully focus on what they see inside a patient's anatomy without having to look away at a monitor. The xvision system is invaluable in surgical workflow management and can also reduce stress in the working environment.

Deep Dive:


Patient Solutions



Patient Solutions


Patient Solutions is the 3rd most populous cluster in the Middle East. The cluster expanded by 63% over the past 5 years to reach 101 ventures by the end of last year. It also represents the only cluster in the Middle East with ventures headquartered across 6 different countries. However, funding remains exclusive to Israel at this point.

Proportion of Patient Solutions Ventures in the Middle East




- Patient Solutions
- Other Digital Health Categories

Venture Distribution by Country, H1 2021



Cumulative No. of Ventures, 2016 - 2020



* Ventures with multiple solutions may be classified in more than 1 category

Venture Spotlight



DayTwo

COUNTRY	PRIMARY CATEGORY
Israel	Disease Management
LATEST FUNDING	VALUATION*
\$37.0M (Series C)	\$217.7M
INC. DATE	MATURITY SCORE
6/2015	74.7


DESCRIPTION

DayTwo is a microbiome-based precision medicine company developing personalized nutrition, diagnostic, and therapeutic solutions using artificial intelligence and machine learning. The company's database of the gut microbiome is the foundation for the DayTwo Human Discovery Platform, which identifies precision medicine therapies, diagnostics, and care solutions for metabolic and other diseases.


©2021 by Galen Growth - All rights reserved.

Patient Solutions

Middle East Value of Venture Capital Investment in Patient Solutions



Total Funding Distribution (2017 - H1 2021) by Country in the Middle East



Venture Spotlight



Medisafe

COUNTRY
Israel

PRIMARY CATEGORY
Digital Therapeutics

LATEST FUNDING
\$30.0M
(Series C)

VALUATION*
\$176.5M


INC. DATE
8/2012

MATURITY SCORE
72.3


DESCRIPTION

Medisafe provides a cloud-synced platform that supplies patients with tools, support, and information designed to help them take their medications correctly and adhere to complicated medication schedules.

Middle East Patient Solutions Investment Volume Share by Venture Stage



Total Funding Distribution (2017 - H1 2021) by District in Israel















Middle East

Noteworthy



MIDDLE EAST: NOTEWORTHY







Noteworthy Deals

Startup	Investors	Country	Category	Stage	Date	Deal Value (\$)
 K Health	 	Israel	Diagnosis Tools	Series E	1 / 2021	\$132.0M
 C2i Genomics		Israel	Genomics Related Diagnosis	Series B	4 / 2021	\$100.0M
 Notal Vision	 	Israel	Diagnosis Tools	Series D	6 / 2021	\$60.0M
 TytoCare		Israel	Remote Monitoring Devices	Series D1	3 / 2021	\$50.0M
 Hello Heart		Israel	Disease Management	Series C	5 / 2021	\$45.0M

MIDDLE EAST: NOTEWORTHY











Noteworthy Exits (M&A)

The first half of 2021 saw 3 M&A in Middle East. This constituted 5% of a total of 55 M&A across four global regions.

Startup	Acquirer	Country	Category	Date	Deal Value (\$)
 MyHeritage	 Francisco Partners	Israel	Genomics Related Applications	2 / 2021	\$600.0M
 PeriGen	 Halma	Israel	Remote Monitoring Devices	4 / 2021	\$58.0M
 Upright Technologies	 DarioHealth	Israel	Wearables	1 / 2021	\$31.0M











MIDDLE EAST: NOTEWORTHY

Most Active Investors

Investor	Type	No. Of Digital Health Deals		Latest Participated Investment	Date	Amount Invested (\$)
		Middle East (2021)	Global (All-Time)			
 OurCrowd	Crowdfunding	2	22	 Medisafe	2 / 2021	\$30.0M
 TriVentures	Venture Capital	2	19	 TailorMed	6 / 2021	\$20.0M
 Qualcomm ventures	Venture Capital	2	15	 TytoCare	3 / 2021	\$50.0M
 octopus ventures	Venture Capital	2	10	 Ibex Medical Analytics	3 / 2021	\$38.0M
 pitango	Venture Capital	1	16	 Medisafe	2 / 2021	\$30.0M

MIDDLE EAST: NOTEWORTHY

Noteworthy Partnerships

Corporate	Startup	Country	Date	Category
 Novogene <small>Advancing Genomics, Improving Life</small>	 C2i Genomics C2i Genomics	Israel	6 / 2021	Genomics Related Diagnosis
 Blackstone, Anthem	 K Health K Health	Israel	4 / 2021	Diagnosis Tools
 Med Right	 Vezeeta Vezeeta	United Arab Emirates	2 / 2021	Teleconsultation
 MultiMed <small>MultiMed SRT</small>	 TytoCare™ <small>Your On Demand Medical Exam</small>	Israel	4 / 2021	Remote Monitoring Devices
 Philips	 IBEX Ibex Medical Analytics	Israel	4 / 2021	Medical Imaging

Key Information



Key Information

Scope of Report

This report covers HealthTech ventures with incorporation date after 2002 in the Middle East. Ventures incorporated outside of the Middle East have not been included in this analysis.

HealthTech is defined as the intersection between healthcare and technology, and is also referred to as digital health. HealthTech does not include Biotech (protein research or pharmaceuticals), MedDev (devices that are mechanical and electronic in nature), neuro-stimulates, opioids and minimal-invasive instruments. We recommend reviewing our taxonomy on the next page for further details.

Data Sourcing & Tracking

Galen Growth tracks a comprehensive inventory of key data points ranging from company demographics, funding and valuation to in-market capabilities on a continuously growing and curated list of HealthTech ventures drawn from global markets. Data is collated from primary research, public domain sources (press releases, news, public filings), proprietary analytics and from its unique network.

The information is:

- Disclosed and undisclosed by nature
- Continuously updated with the latest data
- Curated from both direct and indirect verified sources
- Augmented with our proprietary algorithms

Each HealthTech Alpha Index and Score is calculated using proprietary algorithms and data points drawn from our carefully curated HealthTech Alpha database. We recommend reviewing our venture spotlights for further insights.

Key Terms & Definitions

BASE CURRENCY	USD
EARLY STAGE	All deals up to and including Pre-A & Series A stage
GROWTH STAGE	All deals at Series B & C stage
LATE STAGE	All deals at Series D & Beyond stage
EXIT	IPO, SPAC and M&A deals
HTA	HealthTech Alpha

Important Information

This report is provided solely for informational purposes and was prepared in good faith on the basis of public information available at the time of publication without independent verification. Numbers will be updated from time to time to reflect information identified after the event.

Galen Growth does not guarantee or warrant the reliability or completeness of the data nor its usefulness in achieving any particular purposes.

Galen Growth shall not be liable for any loss, damage, cost or expense incurred by reason because of any persons use or reliance on this report.

This report is a proprietary aggregation of publicly available and undisclosed data and shall not be forwarded or reproduced without the prior written consent of Galen Growth.

Research Enquiries

For more information about data, research and Galen Growth's proprietary algorithm contact: dario.heyman@galengrowth.com for more information.


Analytics Relevant to Decision-Making

Galen Growth's **Alpha Score** is a 360° Venture Maturity assessment that aggregates a set of composite indices, which are calculated for each venture based on our proprietary algorithms that leverage and analyse over 100 million data points.


There are four distinct and independent Alpha Indices:

- Momentum Index:** Evaluates the maturity and performance of the HealthTech venture relative to itself and ecosystem peers
- Market Index:** Measures the health of the sector category and sub-category in which a startup competes
- Money Index:** Quantifies the financial strength and wellbeing of a HealthTech startup based on its financial history, and investor quality
- Innovation Index:** Assesses the relevance of an HealthTech venture to the ecosystem

The **Alpha Score** can be calculated for a venture relative to the Global venture ecosystem or to its National or Regional ecosystem.



Our Digital Health Taxonomy



About Galen Growth





Unleash HealthTech Innovation.

NORTH AMERICA | ASIA PACIFIC | EUROPE | MIDDLE EAST

We enable our clients across the world to achieve their ambitions in Digital Health.

From strategic advisory work, enabling companies to understand complex market problems, scouting for specific HealthTech solutions to solve problem statements, through to corporate venturing.

With our specialist knowledge, Digital Health data and deep connections in the HealthTech ecosystem, we help companies change healthcare for the better.





Global HealthTech Ecosystem Coverage.

Our unmatched coverage of the world's most innovative HealthTech ventures means more innovation choice and better outcomes. Our Asia and European offices serve clients worldwide.

Specialist Team with Decades of Experience

With decades of experience, our team of analysts, researchers, insurance & pharmaceutical industry experts, extend your team with specialist insights and skills.



Tailored Innovation Solutions.

Whatever stage you are in your innovation journey, we have a world class solution to enable you to succeed. Every solution leverages our unrivalled HealthTech data.

Our Differentiators

Our unique combination of data, analytics, specialist team and Digital Health network, enables our clients to outperform their competition.

With Our Network of Entrepreneurs and Experts, We Make the Connections That Drive Innovation Forward.

We are the world's digital health insight network, connecting clients and investors with insights from our network of digital health experts, entrepreneurs and startups and throughout the year.



Quarterly Deal Factory sessions give investors and clients opportunities to hear pitches from promising startups.



Global HealthTech Summit, our marquee event, with access to the most promising HealthTech startups, panel discussions, cutting edge thought leadership & strategic networking.



Our annual HealthTech Cohort supports digital health ventures across the globe.



HealthTech Alpha

Real-time data, analysis and news at your fingertips

HealthTech Alpha empowers investors, corporates and startups to fast track their digital health strategy by transforming tens of millions of ecosystem data points into valuable insights, to rapidly and confidently select best fit ventures for growth.

7400+
STARTUPS

7600+
INVESTORS

17000+
PARTNERSHIPS

7000+
CORPORATES



Rapidly Shape
Your Decisions




Unlock Vital
Insights



Accelerate
Your Strategy

Our Partners

International Pharmaceutical & Insurance companies, VC firms & Investors, rely on Galen Growth to deliver against their Digital Health objectives



Featured In

Bloomberg

**FIRSTLOOK
ASIA**



PharmaAsia
The voice of pharmaceutical manufacturing



CHANNEL NEWSASIA

**NIKKEI
ASIAN
REVIEW**



TECHINASIA

**938
NOW**
IN THE KNOW. ON THE GO

THE EDGE
SINGAPORE

FT

FINANCIAL
TIMES

CIO

FROM IDG

MILKEN INSTITUTE
Changing the World in Innovative Ways

Let's Discuss How Galen Growth Can Deliver Your Strategic Healthcare Goals.

Galen Growth Asia Pte Ltd
Singapore

Galen Growth GmbH
Switzerland

Contact Us Now.

For Pharmaceutical & Medical Devices

✉ julien.desalaberry@galengrowth.com

For Insurance

✉ matt.whittingham@galengrowth.com

For Europe

✉ victoria.lamour@galengrowth.com

For Japan

✉ hajime.sato@galengrowth.com

For VC, CVC, PE or Family Offices

✉ helene.champoux@galengrowth.com

For Pharmaceutical & Med Dev APAC

✉ ana.kollcaku@galengrowth.com